Combination chemoimmunotherapy of metastatic breast cancer with 5-fluorouracil, adriamycin, cyclophosphamide, and BCG

G. N. Hortobagyi, J. U. Gutterman, G. R. Blumenschein, C. K. Tashima, M. A. Burgess, L. Einhorn, A. U. Buzdar, Stephen P Richman, E. M. Hersh

Research output: Contribution to journalArticle

48 Citations (Scopus)

Abstract

One hundred and five patients with metastatic breast cancer were treated with 5-fluorouracil, Adriamycin, cyclophosphamide and BCG (FAC-BCG). The results were compared to those observed in a group of 44 patients treated with FAC chemotherapy alone. Although the overall response rates were similar (76% for FAC-BCG and 73% for FAC), the duration of remission was of 9 months for FAC and 14 months for FAC-BCG (p=0.04). Similarly, survival of responding patients treated with FAC-BCG was significantly longer (24 months) than that observed in the chemotherapy alone treated group (15 months). There was no difference in survival or duration on study for non-responders. Response rates were not influenced by dominant site of disease, menopausal status or disease-free interval. The duration of remission and survival, however, were significantly longer for patients with bone and soft tissue involvement than for patients with visceral metastasis. Similarly patients with 1 or 2 metastatic sites survived significantly longer than those with more than 3 organ sites involved (p=0.02). This chemotherapeutic combination is highly effective in inducing remissions. In addition, nonspecific immunotherapy with BCG appears to prolong duration of remission and survival for responding patients.

Original languageEnglish
Pages (from-to)1225-1233
Number of pages9
JournalCancer
Volume43
Issue number4
DOIs
StatePublished - Dec 1 1979
Externally publishedYes

Fingerprint

Mycobacterium bovis
Fluorouracil
Doxorubicin
Cyclophosphamide
Breast Neoplasms
Survival
Drug Therapy
Immunotherapy
Neoplasm Metastasis
Bone and Bones

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Hortobagyi, G. N., Gutterman, J. U., Blumenschein, G. R., Tashima, C. K., Burgess, M. A., Einhorn, L., ... Hersh, E. M. (1979). Combination chemoimmunotherapy of metastatic breast cancer with 5-fluorouracil, adriamycin, cyclophosphamide, and BCG. Cancer, 43(4), 1225-1233. https://doi.org/10.1002/1097-0142(197904)43:4<1225::AID-CNCR2820430410>3.0.CO;2-6

Combination chemoimmunotherapy of metastatic breast cancer with 5-fluorouracil, adriamycin, cyclophosphamide, and BCG. / Hortobagyi, G. N.; Gutterman, J. U.; Blumenschein, G. R.; Tashima, C. K.; Burgess, M. A.; Einhorn, L.; Buzdar, A. U.; Richman, Stephen P; Hersh, E. M.

In: Cancer, Vol. 43, No. 4, 01.12.1979, p. 1225-1233.

Research output: Contribution to journalArticle

Hortobagyi, GN, Gutterman, JU, Blumenschein, GR, Tashima, CK, Burgess, MA, Einhorn, L, Buzdar, AU, Richman, SP & Hersh, EM 1979, 'Combination chemoimmunotherapy of metastatic breast cancer with 5-fluorouracil, adriamycin, cyclophosphamide, and BCG', Cancer, vol. 43, no. 4, pp. 1225-1233. https://doi.org/10.1002/1097-0142(197904)43:4<1225::AID-CNCR2820430410>3.0.CO;2-6
Hortobagyi, G. N. ; Gutterman, J. U. ; Blumenschein, G. R. ; Tashima, C. K. ; Burgess, M. A. ; Einhorn, L. ; Buzdar, A. U. ; Richman, Stephen P ; Hersh, E. M. / Combination chemoimmunotherapy of metastatic breast cancer with 5-fluorouracil, adriamycin, cyclophosphamide, and BCG. In: Cancer. 1979 ; Vol. 43, No. 4. pp. 1225-1233.
@article{5b85bebf370f420ab4447824d4e46f0b,
title = "Combination chemoimmunotherapy of metastatic breast cancer with 5-fluorouracil, adriamycin, cyclophosphamide, and BCG",
abstract = "One hundred and five patients with metastatic breast cancer were treated with 5-fluorouracil, Adriamycin, cyclophosphamide and BCG (FAC-BCG). The results were compared to those observed in a group of 44 patients treated with FAC chemotherapy alone. Although the overall response rates were similar (76{\%} for FAC-BCG and 73{\%} for FAC), the duration of remission was of 9 months for FAC and 14 months for FAC-BCG (p=0.04). Similarly, survival of responding patients treated with FAC-BCG was significantly longer (24 months) than that observed in the chemotherapy alone treated group (15 months). There was no difference in survival or duration on study for non-responders. Response rates were not influenced by dominant site of disease, menopausal status or disease-free interval. The duration of remission and survival, however, were significantly longer for patients with bone and soft tissue involvement than for patients with visceral metastasis. Similarly patients with 1 or 2 metastatic sites survived significantly longer than those with more than 3 organ sites involved (p=0.02). This chemotherapeutic combination is highly effective in inducing remissions. In addition, nonspecific immunotherapy with BCG appears to prolong duration of remission and survival for responding patients.",
author = "Hortobagyi, {G. N.} and Gutterman, {J. U.} and Blumenschein, {G. R.} and Tashima, {C. K.} and Burgess, {M. A.} and L. Einhorn and Buzdar, {A. U.} and Richman, {Stephen P} and Hersh, {E. M.}",
year = "1979",
month = "12",
day = "1",
doi = "10.1002/1097-0142(197904)43:4<1225::AID-CNCR2820430410>3.0.CO;2-6",
language = "English",
volume = "43",
pages = "1225--1233",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "4",

}

TY - JOUR

T1 - Combination chemoimmunotherapy of metastatic breast cancer with 5-fluorouracil, adriamycin, cyclophosphamide, and BCG

AU - Hortobagyi, G. N.

AU - Gutterman, J. U.

AU - Blumenschein, G. R.

AU - Tashima, C. K.

AU - Burgess, M. A.

AU - Einhorn, L.

AU - Buzdar, A. U.

AU - Richman, Stephen P

AU - Hersh, E. M.

PY - 1979/12/1

Y1 - 1979/12/1

N2 - One hundred and five patients with metastatic breast cancer were treated with 5-fluorouracil, Adriamycin, cyclophosphamide and BCG (FAC-BCG). The results were compared to those observed in a group of 44 patients treated with FAC chemotherapy alone. Although the overall response rates were similar (76% for FAC-BCG and 73% for FAC), the duration of remission was of 9 months for FAC and 14 months for FAC-BCG (p=0.04). Similarly, survival of responding patients treated with FAC-BCG was significantly longer (24 months) than that observed in the chemotherapy alone treated group (15 months). There was no difference in survival or duration on study for non-responders. Response rates were not influenced by dominant site of disease, menopausal status or disease-free interval. The duration of remission and survival, however, were significantly longer for patients with bone and soft tissue involvement than for patients with visceral metastasis. Similarly patients with 1 or 2 metastatic sites survived significantly longer than those with more than 3 organ sites involved (p=0.02). This chemotherapeutic combination is highly effective in inducing remissions. In addition, nonspecific immunotherapy with BCG appears to prolong duration of remission and survival for responding patients.

AB - One hundred and five patients with metastatic breast cancer were treated with 5-fluorouracil, Adriamycin, cyclophosphamide and BCG (FAC-BCG). The results were compared to those observed in a group of 44 patients treated with FAC chemotherapy alone. Although the overall response rates were similar (76% for FAC-BCG and 73% for FAC), the duration of remission was of 9 months for FAC and 14 months for FAC-BCG (p=0.04). Similarly, survival of responding patients treated with FAC-BCG was significantly longer (24 months) than that observed in the chemotherapy alone treated group (15 months). There was no difference in survival or duration on study for non-responders. Response rates were not influenced by dominant site of disease, menopausal status or disease-free interval. The duration of remission and survival, however, were significantly longer for patients with bone and soft tissue involvement than for patients with visceral metastasis. Similarly patients with 1 or 2 metastatic sites survived significantly longer than those with more than 3 organ sites involved (p=0.02). This chemotherapeutic combination is highly effective in inducing remissions. In addition, nonspecific immunotherapy with BCG appears to prolong duration of remission and survival for responding patients.

UR - http://www.scopus.com/inward/record.url?scp=0018777679&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018777679&partnerID=8YFLogxK

U2 - 10.1002/1097-0142(197904)43:4<1225::AID-CNCR2820430410>3.0.CO;2-6

DO - 10.1002/1097-0142(197904)43:4<1225::AID-CNCR2820430410>3.0.CO;2-6

M3 - Article

VL - 43

SP - 1225

EP - 1233

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 4

ER -